cyrilzakka/clinical-trials huggingface dataset:
Resistive Diaphragmatic Training vs Volumes-Oriented Spirometer In Asthmatic Parients

Asthma, a chronic lung disease characterized by airway inflammation and constriction, presents ongoing challenges despite advancements in treatment. The aim of this study to deliver non-pharmacological interventions, particularly comparing resistive diaphragmatic training (RDT) and volume-oriented spirometry, to assess their efficacy in enhancing pulmonary function and functional capacity among asthmatic patients. it will compare resistive diaphragmatic training (RDT) with volume-oriented spirometry in asthmatic patients to pinpoint the superior method for enhancing lung function and daily capabilities.

Asthma is a chronic lung disease characterized by airway inflammation and constriction, presents ongoing challenges despite advancements in treatment.The aim of this study is to deliver non-pharmacological interventions, comparing resistive diaphragmatic training (RDT) and volume-oriented spirometry, to assess their efficacy in enhancing pulmonary function and functional capacity among asthmatic patients. Method: This study will be conducted at "Gulab Devi Chest Hospital" Lahore, it is randomized clinical trial (RCT) which will divided into two groups: Group A include RDT along conventional physiotherapy treatment and Group B include volume-oriented spirometry along conventional physiotherapy treatment. Total 50 subjects will be recruited according inclusion and exclusions criteria by convenient sampling technique. Data collection procedure will follow standardized procedures like pre-assessment and post-assessment which will be after 6 weeks with spirometry, 6MWT, and the ACT. Hypothesis postulated that RDT will show greater mprovements in pulmonary function and functional capacity compared to volumes oriented spirometry. However, null hypothesis will suggest that there is no significant difference between the two interventions.

Eligibility Criteria:
Inclusion Criteria:

* Age range between 35 years to 50 years who must have a confirm diagnosis of asthma and FEV1% \>60% \& \<80%, both male and female with moderate asthma. Outpatients from regional medical Centre.

Exclusion Criteria:

* Asthma patients whose condition require hospitalization asthmatic patients with physical limitation patients, with exercise-induced asthma, Asthma patients with heart dis¬ease with evidence of cardiovascular osteoarticular, inability to consent or cooperate, long-term, home oxygen therapy, active tuberculosis or other infectious disorders as well as stroke, are excluded
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time.

We therefore plan to investigate the feasibility and efficacy of open-label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment-resistant patients. The results from this study could lead to the development of new strategies for the treatment of patients with TRD.

Patients will undergo two weeks of prospective observation, they will then receive IV infusions of ketamine, scopolamine or both per randomization as augmentation of their ongoing antidepressant regime. The schedule of administration will be twice a week of three weeks. After this phase the subject will be followed with assessments every two weeks for three months.

Eligibility Criteria:
Inclusion Criteria:

* Outpatients with sever treatment-resistant depression
* Currently depressed
* Currently under regular psychiatric care
* On an aggressive antidepressant regimen, stable for 4 weeks

Exclusion Criteria:

* No history of other major psychiatric illnesses, including bipolar disorder
* No history of psychosis
* No history of drug abuse
* No major medical illness or unstable medical condition.
Duke Autoimmunity in Pregnancy Registry

It is difficult to predict how a women with an autoimmune disease will do during pregnancy. Some women will improve, others will worsen. Some pregnancies progress normally and others become very complicated.

The Duke Autoimmunity in Pregnancy (DAP) Registry will enroll women with autoimmune diseases, such as lupus, rheumatoid arthritis, scleroderma, and Sjogren's syndrome who wish to become, or already are, pregnant. We will follow these women throughout pregnancy to better understand how their autoimmune disease affects their pregnancy, and vice versa.

Women with a systemic autoimmune disease that would be followed by a rheumatologist will be included in this study.

All women will be seen every 4-6 weeks throughout pregnancy. At each visit, women will complete a questionnaire, the physician will determine the current level of disease activity, and a blood sample will be taken. For women with lupus and healthy women, and additional visit will occur at the start of the 3rd trimester for a closer evaluation of predictors of preterm birth.

This is not an intervention study. Women will not be given experimental medication. All recommendations for treatment and monitoring will be made based on the best available data with input from the treating obstetrician.

Women in this Registry are not required to be seen by Duke Obstetrics nor to deliver at a Duke Hospital.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Desire for pregnancy within 6 months or currently pregnant
* Women with systemic autoimmune disease, including:

  * Lupus (systemic lupus erythematosus or cutaneous lupus)
  * Antiphospholipid Syndrome or positive antiphospholipid antibodies
  * Rheumatoid Arthritis
  * Scleroderma (systemic sclerosis)
  * Sjogren's Syndrome
  * Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)
  * Undifferentiated Connective Tissue Disease (UCTD)
  * Vasculitis
  * Myositis (Polymyositis or Dermatomyositis)
  * Positive Ro/SSA or La/SSB antibodies

Exclusion Criteria:

* Unable to speak English
* Unable to provide informed consent
* Unable to travel to Duke University for follow-up visits
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.


Eligibility Criteria:
Inclusion Criteria:

* Subject is healthy and between the ages of 18 and 55 years, inclusive, at Screening
* Female subjects must weigh between 45 and 100 kg, inclusive, with a BMI between 19.0-29.9 kg/m2, inclusive at Screening. Male subjects must weigh between 50 and 120 kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening
* Subject has a medical history, physical examination, vital signs, ECG and clinical laboratory results within normal limits or considered not clinically significant by the Investigator at Screening

Exclusion Criteria:

* Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations.
* Subject has a history of anaphylaxis, a documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug
* Subject has a clinically significant history of neurological, cardiovascular,respiratory, endocrine, hematological, hepatic, renal, gastrointestinal,genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
Effects of Three Different Methods Applied to Patients After Spine Surgery on Nausea, Thirst and Comfort

The aim of this study was to determine the effects of postoperative methods on nausea, thirst and comfort levels of patients undergoing spinal surgery.

Within the scope of this randomized controlled study, it is aimed to evaluate the effectiveness of ice, mouthwash and menthol lozenge interventions to provide effects on postoperative nausea, thirst and comfort in patients undergoing spinal surgery

Eligibility Criteria:
Inclusion Criteria:

* Adult patients who underwent lumbar disc herniation (LDH) surgery
* LDH surgery patients who recieve general anesthesia
* The patients who were conscious
* The duration of surgery is between 0-3 hours

Exclusion Criteria:

* Patients who cannot understand and speak Turkish
* Allergic patients to menthol
* Patients who received spinal anesthesia
* Patients with lesions on the oral mucosa and lips
* Patients requiring intensive care after surgical intervention
Negative Pressure Wound Therapy for Surgical Site Infection Prevention in Common Femoral Artery Exposure

The purpose of this randomized clinical trial is to investigate the role of negative pressure wound therapy (NPWT) vs standard sterile gauze therapy on the incidence of surgical site infections (SSI) in primarily closed groin incisions in high risk patients undergoing any open common femoral artery exposure for a vascular surgery procedure.

Eligible patients are randomized pre-operatively into either a standard dressing or NPWT for the groin incision.

* 1 The control group receive a standard sterile gauge dressing over the groin incision. The dressing is removed on post-operative day #2 and the wound is inspected for a SSI or dehiscence, followed by daily dressing changes and wound inspections until discharge.
* 2 The intervention group will receive a NPWT dressing which will be applied in the operating room under sterile conditions. The NPWT dressing will be removed on Post operative day 5. The wound is inspected for a SSI or dehiscence, followed by daily dressing changes and wound inspections until discharge.

Eligibility Criteria:
Inclusion Criteria: One or more of the following

* Body Mass Index \>30 kg/m2
* Critical limb ischemia defined by Ankle Brachial Index\<0.35, rest pain, tissue loss and/or non-healing ulcers
* Procedure time \>240 min
* End Stage Renal Disease on dialysis
* Glycated hemoglobin ≥ 8.5%
* Transfusion ≥ 3 units packed Red Blood Cells
* Previous femoral artery cut-down

Exclusion Criteria:Any of the following

* Preexisting groin infection
* Complete vacuum seal cannot be achieved with negative pressure device
* Allergy to Adhesive Material
* Groin Surgery within last 30 days
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

PRIMARY OBJECTIVES:

I. Comparison of fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) accumulation with fludeoxyglucose F-18 (18F-FDG) accumulation to assess whether (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate (18F-FSPG)-PET is better at discriminating between benign and malignant nodules.

SECONDARY OBJECTIVES:

I. To develop and validate early lung cancer detection biomarkers that would directly impact the growing need to integrate imaging and non-invasive molecular diagnostics for indeterminate pulmonary nodules and allow physicians to avoid unnecessary invasive procedures in patients with benign lung disease.

OUTLINE:

Patients receive 18F-FSPG intravenously (IV) and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG and undergo a second PET/CT scan over 30-60 minutes.

After completion of study, patients are followed up within 24-72 hours.

Eligibility Criteria:
Inclusion Criteria:

* Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
* Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
* Current or former cigarette smoker, with \>= 20 pack years
* Documented informed consent

Exclusion Criteria:

* History or previous diagnosis of lung cancer
* Cancer diagnosis within the last 5 years
* Pregnant or nursing
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.


Eligibility Criteria:
Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Study to Evaluate Broadlumab vs Placebo and Ustekinumab

The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.

The study is up to 5 years. If you qualify, you will be randomized into 1 of 4 groups. Two groups will get brodalumab(1 group will get 210milligrams of brodalumab at each dose and the other group will get 140 milligrams of brodalumab at each dose), one group will get ustekinumab, and one group will get placebo.

Eligibility Criteria:
Inclusion Criteria:

* Subject has had stable moderate to severe plaque psoriasis for at least 6 months before first dose of IP.
* Subject has involved body surface area \>_10%, PASI\>_, and sPGA\>_3 at screening and at baseline.
* For women, a negative serum pregnancy test during screening a negative urine pregnancy test at baseline.
* Subject has no known history of active tuberculosis.
* Subject has a negative test for tuberculosis during screening.

Exclusion Criteria:

* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at the time of the screening visit that would interfere with evaluations of the effect of IP on psoriasis.
* Subject has a planned surgical intervention between baseline and the week 52 evaluation.
* Subject an active infection or history of infections.
* Subject has any systemic disease considered by the investigator to be clinically significant and uncontrolled.
* Subject has known history of Crohn's disease.
* Subject has known history of hepatitis B, hepatitis C, or human immunodeficiency virus.
* Subject had myocardial infarction or unstable angina pectoris within the past 12 months prior to the first dose of IP.
* Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
* Subject has history of malignancy within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.
* Subject has received live vaccine(s) within 28 days of the first dose of IP.
* Subject has used ustekinumab and/or antio-IL-17 biologic therapy ever or other experimental or commercially available biologi immune modulator(s) within 12weeks prior to the first IP dose
* Subject currently is enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s).
* For women not willing to use highly effective methods of birth control during treatment and for 15 weeks after the last dose.
* For women; pregnant or breast feeding, or planning to become pregnant while enrolled in the study and for 15 weeks after the last dose.
Screening for Early Cervical Cancer Detection

This study is to audit results and adherence to Cervical Screening program before and after the implementing awareness of the WHO guidelines of screening among the multidisciplinary healthcare workers and patients.

Cervical cancer screening is the asymptomatic detection of pre-cancer and cancer in women at risk, with at least one screening suggested for women aged 30-49 years. According to the World Health Survey (2015), 19% of eligible women in developing countries and 63% of those in developed nations had their cervical cancer screening done using a Pap smear or visual inspection with acetic acid (VIA).

According to latest estimates by World Health Organization (WHO), in Egypt, 866 women are diagnosed with cervical cancer every year and 373 die from the disease. Cervical cancer is the 13th most common cancer in women in Egypt and the 10th most common cancer in women aged between 15 to 44 years . Statistics from Egyptian studies provide pre invasive cervical lesion incidence levels of 0.3 % to 0.5 % .

The human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. HPV can be transmitted through sexual contact, including vaginal or oral sex with an infected person. HPV has more than 100 strains, of which HPV16 and HPV18 account for about 70% of invasive cervical cancers

Eligibility Criteria:
Inclusion Criteria:

* Women 20-60 years.

  * Sexually active.
  * Fulfilling Cervical Check's eligibility criteria for screening at the time of the audit https://www.cervicalcheck.ie/_fileupload/File/Eligibility%20Framework.pdf

Exclusion Criteria:

Patient who had underwent to total hysterectomy.

* Pregnant or postpartum or post abortive patients
* Patient having any history of treatment for cervical dysplasia.
* Immunocompromised patients.
Reliability of Clinical Limb-length Measurements Methods

There are numerous ways to measure limb length discrepancy in the clinical practice, although their reliability and accuracy are not well known. In our prospective diagnostic study we aimed to test the most popular methods and compare their results to EOS 3D reconstructions data.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18-30 years
* BMI: \< 30
* Without orthopaedic complaint

Exclusion Criteria:

* Previous surgery on lower limb or spine
* Developmental disorder in the patients history
Schistosoma Haematobium Infections and Praziquantel

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.

A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.

Eligibility Criteria:
Inclusion Criteria:

* School children

Exclusion Criteria:

* Taking praziquantel
The Use Of Pontic Shield Technique For Alveolar Ridge Preservation . A Case Series

To assess bucco-lingual dimension of the ridge while using pontic shield technique as a treatment modality for ridge preservation

• Patients with non-restorable teeth in the esthetic area will be recruited from Faculty of Dentistry in Cairo University A pre-operative cone beam computed tomography ( CBCT ) will be taken to examine the non-restorable tooth , measure bucco-lingual width and exclude any fenestration or dehiscence in the labial bone plate

A non-surgical phase one therapy will be done for the patient as a preparatory phase

Proper oral hygiene measures and chlorohexidene mouthwash will be prescribed after the the first

Reassessment of the case to assure absence of any signs of inflammation and prescence of normal tissues before the surgical procedure

* The area will be anaesthetized using infiltration technique in labial site with 1.5ml of anaesthetic solution and palatal site with 0.3 ml of anaesthetic solution
* Decoronation of the tooth , if the crown is available, will be done to obtain a concave mesio-distal root
* A long shank root resection bur will be used to section the root mesiodistally as far apical as possible , in order to obtain the buccal half attached to the labial bone plate and together the apical and the palatal half will be attached to the palatal bone
* Periotome will be used to distort the periodontal ligaments between the palatal half of the root and palatal alveolar socket wall
* Together the apical and the palatal portions of the root will be delivered , using micro forceps
* Bone curettage will be done in the presence of peraipical infection
* Explorer will be used to exclude mobility of the buccal portion of the root
* The thickness of the buccal portion will be reduced to 2mm
* A large round bur will be used to reduce the height of the buccal portion in a mesiodistal direction.
* A bone grafting material will be placed in the remaining socket

Eligibility Criteria:
1-Inclusion Criteria:

1a- non-restorable teeth in the anterior esthetic zone

1b-Teeth not indicated for immediate implant placement for reasons such as acute periapical infection, insufficient buccolingual width, poor economical status

1c- Full mouth plaque score (FMPS )\<25% at baseline

1d- Full mouth bleeding score (FMBS )\<25% at baseline

1e -Systemically healthy

2-Exclusion Criteria:

2a- Fenestration or dehiscence in buccal plate 2b- Periodontally compromised tooth 2c- Mobility of the tooth or remaining root 2d- Smokers 2e- Pregnancy and lactation
Evaluation of Visual Acuity and Patient Satisfaction With AT LISA TRI 839MP Intraocular Lenses

The purpose of the study is to evaluate the far, intermediate and near visual acuities with a trifocal IOL.

After bilateral cataract surgery, monocular and binocular uncorrected (UCVA) and best distance corrected visual acuity (BCVA) will be measured at far (4m), intermediate (80 cm) and near (40 cm) distance as well as the subjective refraction.

A patient questionnaire will be used to assess the patient satisfaction and spectacle independence.

Eligibility Criteria:
Inclusion Criteria:

* Man or woman, over 50 years of age
* Bilateral implantation of a trifocal intraocular lens
* Capsular bag implantation

Exclusion Criteria:

* Existing ocular pathology
* Surgical complications
* Corneal astigmatism ≥ 1.0D